Clicky

Oneness Biotech Co Ltd(4743)

Description: Oneness Biotech Co., Ltd. engages in the research, development, and sale of new drugs, pharmaceutical, and health products in Taiwan. It operates through New Drug Research and Development, and Agricultural Products Cultivation segments. The company develops ON101, which is in Phase III clinical trials for treating chronic diabetic foot ulcers; and OB318, an anti-cancer drug that is in Phase I clinical trials. It is also developing FB704A that has completed Phase I clinical trial for the treatment of rheumatoid arthritis; FB825, which is in Phase IIa clinical trial for treating atopic dermatitis, allergic diseases, and asthma; and FB918, an antibody targeting the interleukin 33 that is in pre-clinical stage for the treatment of asthma. In addition, the company engages in the management of agriculture cultivation and trading business; and sale of agricultural products. Oneness Biotech Co., Ltd. was incorporated in 2008 and is headquartered in Taipei, Taiwan.


Keywords: Medicine Health Care Agricultural Products Health Products Monoclonal Antibodies Rheumatoid Arthritis Asthma Atopic Dermatitis Allergic Diseases Fb825 On101

Home Page: www.onenessbio.com

No.236, Xinyi Road
Taipei, 106
Taiwan
Phone: 886 2 2703 1098


Officers

Name Title
Ms. Chih-Hui Cheng GM & Supervisor of Corp. Governance
Ms. Debbie Fang Mang. of Fin. Department
Ms. Wen-Tzu Hsiao Acting Spokesperson & Sr. Mang. of Fin. Department
Shyi-Gen Chen M.D., M.P.H. VP & Head of Medical Affairs
Dr. Jui-Ching Chen Ph.D. Director of New Drug Devel. Department
Mr. Kung-Ming Lu Director of Operation Center
Mr. Nien-Yi Chen Deputy Gen. Mang. of Antibody New Drug Division;

Exchange: TWO

Country: TW

Currency: New Taiwan Dollar (NT$)

Forward PE: 0
Trailing PE: 83.4532
Price-to-Book MRQ: 6.5357
Price-to-Sales TTM: 88.1683
IPO Date:
Fiscal Year End: December
Full Time Employees: 0
Back to stocks